XML 41 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
12 Months Ended
Feb. 12, 2016
Dec. 31, 2016
Dec. 31, 2015
Cash Equivalents, at Carrying Value   $ 0 $ 0
Goodwill, Fair Value Disclosure $ 0    
Goodwill, Impairment Loss   $ 404,169
Fair Value Assumptions, Expected Dividend Rate   0.00%  
Derivative, Gain (Loss) on Derivative, Net   $ (29,445)
Private Placement [Member] | Series B Preferred Stock [Member] | Strategic Bio Partners [Member] | Debt Settlement [Member]      
Class of Warrant or Right, Issued 295,945    
Private Placement [Member] | Series B Preferred Stock [Member] | Placement Agent Warrants [Member]      
Class of Warrant or Right, Issued 127,346    
Protagenic Therapeutics Inc [Member]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $ 0    
Equipment [Member]      
Property, Plant and Equipment, Useful Life   3 years